FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1986793532> ?p ?o ?g. }

• W1986793532 endingPage "66" @default.
• W1986793532 startingPage "61" @default.
• W1986793532 abstract "Purpose: Between June 1988 and June 1994, 38 hemangioblastomas were treated with stereotactic radiosurgery (SR) at three SR centers to evaluate the efficacy and potential toxicity of this therapeutic modality as an adjuvant or alternative treatment to surgical resection.Methods and Materials: SR was performed using either a 201-cobalt source unit or a dedicated SR linear accelerator. Of the 18 primary tumors treated, 16 had no prior history of surgical resection and were treated definitively with SR and two primary lesions were subtotally resected and subsequently treated with SR. Twenty lesions were treated with SR after prior surgical failure (17 tumors) or failure after prior surgery and conventional radiotherapy (three tumors). Eight patients were treated with SR for multifocal disease (total, 24 known tumors). SR tumor volumes measured 0.05 to 12 cc (median: 0.97 cc). Minimum tumor doses ranged from 12 to 20 Gy (median: 15.5 Gy).Results: Median follow-up from the time of SR was 24.5 months (range: 6–77 months). The 2-year actuarial overall survival was 88 ± 15% (95% confidence interval). Two-year actuarial freedom from progression was 86 ± 12% (95% confidence interval). The median tumor volume of the lesions that failed to be controlled by SR was 7.85 cc (range: 3.20–10.53 cc) compared to 0.67 cc (range: 0.05–12 cc) for controlled lesions (p = 0.0023). The lesions that failed to be controlled by SR received a median minimum tumor dose of 14 Gy (range: 13–17 Gy) compared to 16 Gy (range: 12–20 Gy) for controlled lesions (p = 0.0239). Seventy-eight percent of the surviving patients remained neurologically stable or clinically improved. There were no significant permanent complications directly attributable to SR.Conclusions: This report documents the largest experience in the literature of the use of SR in the treatment of hemangioblastoma. We conclude that SR: (a) controls the majority of primary and recurrent hemangioblastomas; (b) offers the ability to treat multiple lesions in a single treatment session, which is particularly important for patients with Von Hippel-Lindau Syndrome; and that (c) better control rates are associated with higher doses and smaller tumor volumes." @default.
• W1986793532 created "2016-06-24" @default.
• W1986793532 creator A5006457291 @default.
• W1986793532 creator A5056042324 @default.
• W1986793532 creator A5073146819 @default.
• W1986793532 date "1976-01-01" @default.
• W1986793532 modified "2023-09-30" @default.
• W1986793532 title "Hippel-Lindau syndrome" @default.
• W1986793532 cites W129642105 @default.
• W1986793532 cites W1963784501 @default.
• W1986793532 cites W1971177370 @default.
• W1986793532 cites W1996393779 @default.
• W1986793532 cites W2035734782 @default.
• W1986793532 cites W2048643989 @default.
• W1986793532 cites W2062803307 @default.
• W1986793532 cites W2100161232 @default.
• W1986793532 cites W2313307629 @default.
• W1986793532 cites W2415880873 @default.
• W1986793532 cites W2427600271 @default.
• W1986793532 doi "https://doi.org/10.1016/0037-198x(76)90064-x" @default.
• W1986793532 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/943128" @default.
• W1986793532 hasPublicationYear "1976" @default.
• W1986793532 type Work @default.
• W1986793532 sameAs 1986793532 @default.
• W1986793532 citedByCount "13" @default.
• W1986793532 countsByYear W19867935322013 @default.
• W1986793532 countsByYear W19867935322017 @default.
• W1986793532 crossrefType "journal-article" @default.
• W1986793532 hasAuthorship W1986793532A5006457291 @default.
• W1986793532 hasAuthorship W1986793532A5056042324 @default.
• W1986793532 hasAuthorship W1986793532A5073146819 @default.
• W1986793532 hasConcept C126322002 @default.
• W1986793532 hasConcept C141071460 @default.
• W1986793532 hasConcept C2780387249 @default.
• W1986793532 hasConcept C2989005 @default.
• W1986793532 hasConcept C44249647 @default.
• W1986793532 hasConcept C509974204 @default.
• W1986793532 hasConcept C71924100 @default.
• W1986793532 hasConceptScore W1986793532C126322002 @default.
• W1986793532 hasConceptScore W1986793532C141071460 @default.
• W1986793532 hasConceptScore W1986793532C2780387249 @default.
• W1986793532 hasConceptScore W1986793532C2989005 @default.
• W1986793532 hasConceptScore W1986793532C44249647 @default.
• W1986793532 hasConceptScore W1986793532C509974204 @default.
• W1986793532 hasConceptScore W1986793532C71924100 @default.
• W1986793532 hasIssue "1" @default.
• W1986793532 hasLocation W19867935321 @default.
• W1986793532 hasLocation W19867935322 @default.
• W1986793532 hasOpenAccess W1986793532 @default.
• W1986793532 hasPrimaryLocation W19867935321 @default.
• W1986793532 hasRelatedWork W1586374228 @default.
• W1986793532 hasRelatedWork W2003938723 @default.
• W1986793532 hasRelatedWork W2045240138 @default.
• W1986793532 hasRelatedWork W2047967234 @default.
• W1986793532 hasRelatedWork W2118496982 @default.
• W1986793532 hasRelatedWork W2364998975 @default.
• W1986793532 hasRelatedWork W2369162477 @default.
• W1986793532 hasRelatedWork W2439875401 @default.
• W1986793532 hasRelatedWork W4238867864 @default.
• W1986793532 hasRelatedWork W2525756941 @default.
• W1986793532 hasVolume "11" @default.
• W1986793532 isParatext "false" @default.
• W1986793532 isRetracted "false" @default.
• W1986793532 magId "1986793532" @default.
• W1986793532 workType "article" @default.